Oscotec announced progress across its clinical pipeline, highlighting ADEL-Y01 and candidate compounds OCT-598 and P4899 aimed at overcoming next-generation anticancer treatment resistance.The company did so at the “2025 Second Half R&D Day” held on Monday at the Federation of Korean Industries buil
Samsung is deepening its bet on antibody-drug conjugates (ADCs) with a new equity investment in China-based Phrontline Biopharma, adding capital to an October licensing deal that brought Phrontline’s dual-payload ADC platform into Samsung Bioepis’ oncology pipeline.Samsung Life Science Fund, an inve
Celltrion is accelerating its European market expansion for Omlyclo, a biosimilar referencing Novartis’ Xolair, after completing launches in major markets including Germany, Spain, the U.K., and France.Omlyclo is an antibody biopharmaceutical with the same composition as the original drug, Novartis'
TiUM Bio announced on Tuesday that it has received approval from the World Health Organization (WHO) for the International Nonproprietary Name (INN) of its anticancer drug candidate TU2218 as “tosposertib.”TiUM Bio explained that tosposertib is a combination of “tospo,” meaning “together,” and the s
Korean drugmakers are commissioning facilities designed to pass U.S. and European inspections on the first attempt, and they want those requirements fixed in the blueprint before concrete is poured.AtkinsRéalis, the Montreal-based design and project firm that entered Korea in 2007 and opened a Seoul
Samyang Biopharm was listed on the Korea Exchange (KOSPI) market on Monday. The number of shares listed is 7,435,870.The listing was made through a direct listing following the spin-off from Samyang Holdings, the holding company of the Samyang Group, on Nov. 1. After the spin-off, Samyang Holdings s
ToolGen is teaming up with Hong Kong–based GenEditBio in a cross-licensing deal that weds its CRISPR gene-editing platform to GenEditBio’s lipid nanoparticle delivery system, with an eye on pushing a once-and-done in vivo therapy for atherosclerotic cardiovascular disease into the clinic.The Korean
Vaxcellbio, a Korean biotechnology company specializing in immunotherapy, said it has signed a research agreement with the Korea Drug Development Fund (KDDF), after being selected for the national program “Foundational Research for New Drug Discovery.” Under this agreement, the company will pursue t
GI Innovation said it has received approval for a phase 2a clinical trial from the Bellberry Human Research Ethics Committee in Australia to evaluate a combination anti-aging therapy combining the company’s immunotherapy drug GI-102 and GI Longevity’s microbiome candidate GIB-7.The study marks one o
Celltrion, the Korean drugmaker built on copycat biologics, is spending billions of dollars to refashion itself as something closer to a global pharmaceutical heavyweight, buying and expanding an Eli Lilly plant in New Jersey, pouring money into new factories at home and pushing an experimental oral
The European Commission (EC) has approved a line extension for Celltrion’s Omlyclo (omalizumab), Europe’s first omalizumab biosimilar, authorizing a 300 mg/2 ml pre-filled syringe for use in the European Union.The product previously received approval in May 2024 for the 75 mg per 0.5 ml and 150 mg p
Aimed Bio, the Korean antibody-drug conjugate (ADC) developer behind more than 3 trillion won ($2 billion) in global licensing deals -- including a landmark agreement with Boehringer Ingelheim -- outlined its pipeline strategy and IPO plans on Tuesday as it prepares to debut on the Kosdaq.Founded in
A clinical trial of allogeneic umbilical cord-derived mesenchymal stem cell therapy is underway in Korea for Charcot–Marie–Tooth disease (CMT) type 1A.ENCell said Tuesday it obtained approval from the Ministry of Food and Drug Safety (MFDS) for a phase 2a clinical trial. The trial will test allogene
GC Cell held a commemorative event at its Yongin Cell Center in Gyeonggi Province last Friday to mark World Cord Blood Day.The event featured a range of activities designed to raise awareness of the medical value of cord blood and the importance of its storage. Through these programs, GC Cell aimed
After a decade spent proving its blood-brain barrier (BBB) tech to Sanofi and GSK, ABL Bio is using a new two-part pact with Eli Lilly to argue it is no longer just a shuttle vendor but a Korean biotech ready to fund late-stage cancer assets and next-generation antibody-drug conjugates (ADCs) on its
Pin Therapeutics announced on Monday that it delivered an oral presentation on its TPD platform technology, “PinMARS,” at the 8th Annual TPD & Induced Proximity Summit held in Boston, Mass., and pursued joint R&D discussions with global pharmaceutical and biotech companies.The TPD Summit is the worl
Celltrion has unveiled a three-year plan to invest 4 trillion won ($2.7 billion) in its biomanufacturing and research infrastructure in Korea, positioning Korea as the company’s central production base even as U.S. investment requirements rise under the recently concluded tariff negotiations between
SK biopharmaceuticals said Thursday that it has signed a strategic memorandum of understanding with Seoul Biohub, a biomedical startup support platform established by the Seoul Metropolitan Government, to operate an open innovation program.Open innovation brings in external technologies and ideas to
DuChemBio said Thursday it recorded third-quarter sales of 9.92 billion won ($6.69 million).Third-quarter operating profit rose 63.1 percent year-on-year to 1.9 billion won, with cumulative operating profit up 17.0 percent to 4.45 billion won.The company attributed its growth to the sharp recovery i
ABL Bio is accelerating its entry into the global central nervous system (CNS) disease market through significant international deals, beginning with Sanofi.After its single-asset technology transfer deal with Sanofi, ABL Bio has continued this momentum by signing platform-based agreements with GSK
